EP 3689902 B1 20230628 - FLAVIVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
Title (en)
FLAVIVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
Title (de)
FLAVI-VIRUS-NEUTRALISIERENDE ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON
Title (fr)
ANTICORPS NEUTRALISANTS DE FLAVIVIRUS ET LEURS PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- US 201361792336 P 20130315
- EP 14764455 A 20140314
- US 2014028310 W 20140314
Abstract (en)
[origin: WO2014144061A2] The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAbl 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
IPC 8 full level
C07K 16/10 (2006.01); A61K 39/395 (2006.01); A61P 31/14 (2006.01); C12P 21/06 (2006.01)
CPC (source: EP US)
A61K 39/12 (2013.01 - US); A61P 29/02 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/14 (2017.12 - EP); A61P 37/04 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 16/1081 (2013.01 - EP US); A61K 2039/505 (2013.01 - EP US); A61K 2039/545 (2013.01 - EP US); C07K 2317/24 (2013.01 - US); C07K 2317/524 (2013.01 - EP US); C07K 2317/565 (2013.01 - US); C07K 2317/71 (2013.01 - EP US); C07K 2317/76 (2013.01 - EP US); C12N 2770/24011 (2013.01 - EP US); Y02A 50/30 (2017.12 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2014144061 A2 20140918; WO 2014144061 A9 20141211; AU 2014227909 A1 20150827; AU 2014227909 B2 20180308; AU 2014227909 C1 20211125; AU 2018204011 A1 20180621; AU 2018204011 B2 20190829; AU 2018204011 C1 20211125; BR 112015021341 A2 20170718; BR 112015021341 B1 20230328; CA 2901358 A1 20140918; CA 2901358 C 20220726; EP 2971042 A2 20160120; EP 2971042 A4 20160907; EP 2971042 B1 20200115; EP 3689902 A1 20200805; EP 3689902 B1 20230628; EP 4292657 A2 20231220; EP 4292657 A3 20240320; JP 2016514675 A 20160523; JP 2019054796 A 20190411; JP 6427552 B2 20181121; JP 6734902 B2 20200805; MX 2015013232 A 20151211; MX 2019010339 A 20191014; MX 367668 B 20190830; PH 12015502164 A1 20160125; PH 12015502164 B1 20160125; SG 11201507359S A 20151029; US 10400032 B2 20190903; US 10899825 B2 20210126; US 2016024189 A1 20160128; US 2018251531 A1 20180906; US 2020062830 A1 20200227; US 9822166 B2 20171121
DOCDB simple family (application)
US 2014028310 W 20140314; AU 2014227909 A 20140314; AU 2018204011 A 20180606; BR 112015021341 A 20140314; CA 2901358 A 20140314; EP 14764455 A 20140314; EP 19213985 A 20140314; EP 23181586 A 20140314; JP 2016502756 A 20140314; JP 2018202677 A 20181029; MX 2015013232 A 20140314; MX 2019010339 A 20150915; PH 12015502164 A 20150915; SG 11201507359S A 20140314; US 201414777324 A 20140314; US 201715818491 A 20171120; US 201916514439 A 20190717